Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)
UROCOR
1 other identifier
observational
197
1 country
33
Brief Summary
This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten years using FRAX model in patients with prostate cancer. The patients will be following for 12 months
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2011
33 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 26, 2011
CompletedFirst Posted
Study publicly available on registry
January 27, 2011
CompletedStudy Start
First participant enrolled
March 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2012
CompletedDecember 24, 2012
December 1, 2012
1.8 years
January 26, 2011
December 21, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
Metabolic syndrome
3 months
Metabolic syndrome
6 months
Metabolic syndrome
12 months
Diabetes
3 months
Diabetes
6 months
Diabetes
12 months
Secondary Outcomes (1)
Fracture Risk Assessment Tool (FRAx) assessment
0 and 12 months
Eligibility Criteria
Prostate cancer patients in androgen-ablaction treatment in urological departments
You may qualify if:
- Prostate cancer patient requiring androgen-ablation treatment: LHRH analogs, surgical castration, antiandrogen treatment
- Provision of informed consent prior to conducting any study-related procedure
You may not qualify if:
- Patient involved in a Clinical Trial
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (33)
Research Site
Albacete, Albacete, Spain
Research Site
El Ejido, Almeria, Spain
Research Site
Huercal Overa, Almeria, Spain
Research Site
Mérida, Badajoz, Spain
Research Site
Palma de Mallorca, Balearic Islands, Spain
Research Site
Barcelona, Barcelona, Spain
Research Site
El Hospitalet de Llobregat, Barcelona, Spain
Research Site
Sabadell, Barcelona, Spain
Research Site
Aranda de Duero, Burgos, Spain
Research Site
Miranda de Ebro, Burgos, Spain
Research Site
Córdoba, Cordoba, Spain
Research Site
Ferrol, Coru?a, Spain
Research Site
Granada, Granada, Spain
Research Site
Guadalajara, Guadalajara, Spain
Research Site
Donostia / San Sebastian, Guipuzcoa, Spain
Research Site
Jaén, Jaen, Spain
Research Site
Logroño, La Rioja, Spain
Research Site
Monforte (casco Urbano), Lugo, Spain
Research Site
Alcalá de Henares, Madrid, Spain
Research Site
Coslada, Madrid, Spain
Research Site
Madrid, Madrid, Spain
Research Site
Majadahonda, Madrid, Spain
Research Site
San Sebastián de los Reyes, Madrid, Spain
Research Site
Antequera, Malaga, Spain
Research Site
Vigo, Pontevedra, Spain
Research Site
Osuna, Sevilla, Spain
Research Site
Reus, Tarragona, Spain
Research Site
Toledo, Toledo, Spain
Research Site
Barakaldo, Vizcaya, Spain
Research Site
Bilbao, Vizcaya, Spain
Research Site
Galdakao, Vizcaya, Spain
Research Site
Calatayud, Zaragoza, Spain
Research Site
Zaragoza, Zaragoza, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 26, 2011
First Posted
January 27, 2011
Study Start
March 1, 2011
Primary Completion
December 1, 2012
Study Completion
December 1, 2012
Last Updated
December 24, 2012
Record last verified: 2012-12